Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Fineline Cube Sep 9, 2026
Company Drug

Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III

Fineline Cube Sep 9, 2026
Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Fineline Cube Sep 9, 2026
Company Drug

Ascletis Pharma’s Denifanstat Meets Phase III Endpoints in Severe Acne Trial

Fineline Cube Jun 4, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the Phase III clinical study of its...

Company Deals Drug

Eli Lilly Partners with Camurus on Long-Acting Cardiovascular and Metabolic Health Products

Fineline Cube Jun 4, 2025

US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with...

Company Drug

CirCode Biomed’s Circular RNA Drug HM2002 Approved for US Clinical Trials

Fineline Cube Jun 4, 2025

China-based Shanghai CirCode Biomed Co. Ltd., a specialist in circular RNA therapies, announced that its...

Company Medical Device

Bio-heart Launches Iberis Renal Ablation System at OCC 2025

Fineline Cube Jun 4, 2025

China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its...

Company Deals

BioAge Labs Partners with JiKang for APJ Agonist Nanobody License

Fineline Cube Jun 4, 2025

US-based biotech BioAge Labs, Inc. announced an option agreement with China’s JiKang Therapeutics, potentially securing...

Company Drug

Bayer’s Nubeqa Gets FDA Approval for mHSPC Treatment

Fineline Cube Jun 4, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration...

Company Deals

Sainte Nutritional Files for IPO in Hong Kong as FSMP Pioneer

Fineline Cube Jun 4, 2025

Sainte Nutritional Inc., China’s leading provider of Food for Special Medical Purpose (FSMP), has filed...

Company Drug

Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) presented the results of the Phase III CAMPASS study...

Company Deals

Harbin Gloria Partners with Eisai to Promote Methycobal in China

Fineline Cube Jun 4, 2025

China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has entered into a market promotion service...

Company Drug

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler

Fineline Cube Jun 4, 2025

Beijing-based Lepu Medical Technology (SHE: 300003), a provider of cardiovascular disease solutions, announced that its...

Company Drug

JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025

Fineline Cube Jun 4, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...

Company Drug

Hansoh Pharma’s Almonertinib Approved in UK for EGFR-Mutated NSCLC

Fineline Cube Jun 4, 2025

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved China-based Hansoh Pharmaceutical Group...

Company Medical Device Policy / Regulatory

EU Bars Chinese Medical Device Makers from Public Tenders Over €5M for Five Years

Fineline Cube Jun 4, 2025

China Central Television (CCTV) reported that EU member states have voted under the International Procurement...

Company Drug

Legend Biotech Presents 5-Year Carvykti Data at ASCO 2025

Fineline Cube Jun 4, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) presented 5-year follow-up data from the CARTITUDE-1 study for...

Company Drug

EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen

Fineline Cube Jun 4, 2025

Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...

Company Drug

Biokin Pharma Enrolls First Patient in BL-M07D1 Phase III Trial for HER2 Low Breast Cancer

Fineline Cube Jun 3, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced the enrollment of the first patient...

Company Deals

Sanofi to Acquire Blueprint Medicines for $9.1 Billion to Expand Rare Disease Pipeline

Fineline Cube Jun 3, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) announced plans to acquire US-based Blueprint Medicines Corporation for...

Company Deals

BioNTech Partners with BMS to Jointly Develop BNT327 for Solid Tumors

Fineline Cube Jun 3, 2025

Germany-based BioNTech SE (NASDAQ: BNTX) announced a strategic partnership with US major Bristol-Myers Squibb (BMS,...

Company Deals Drug

Harbin Pharma Agrees to Acquire Clinical Approval for Jesduvroq from Bocimed

Fineline Cube Jun 3, 2025

China’s Harbin Pharmaceutical Group Holding Co., Ltd (SHA: 600664) announced a technology transfer agreement with...

Company Drug

Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025

Fineline Cube Jun 3, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs...

Posts pagination

1 … 202 203 204 … 718

Recent updates

  • Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III
  • CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops
  • Gilead Opens Foster City Research Center for Oncology and Inflammation
  • Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data
  • China Launches Five-Year Plan to Expand High-Quality Eye Health Services
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III

Company Drug

CSPC Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops

Company PIC

Gilead Opens Foster City Research Center for Oncology and Inflammation

Company Drug

Windward’s TSLP Antibody HBM9378 Posts Positive POLARIS-1 Asthma Data

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.